Skip to main content

Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022.

Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call the next day before the market opens on Tuesday, August 9, 2022, at 8:30 a.m. Eastern Time to discuss the financial results and to provide a business update.

Earnings Call and Webcast Details:

The webcast of the earnings call will be live at: Link Directly to Webcast

To attend by telephone, please use the information below for dial-in access.

  • Date and Time: August 9, 2022 – 8:30 a.m. Eastern Time
  • Please register for the call. You can register any time starting now through the call.
  • Link to register at any time: Registration Link
  • Registration in advance is encouraged. You can then choose to be provided with the dial-in and PIN or to use the new “Call Me” feature.

Please visit the Investor Relations website at ir.conformis.com on August 8, 2022, to view the earnings release prior to the webcast and conference call.

The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.

About Conformis, Inc.
Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future press releases via e-mail alerts, sign up at ir.conformis.com.

Contact
Investor Contact:
Investor Relations
ir@conformis.com
(781) 374-5598

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.